Okuda J, Okamoto S, Takahata M, Nishino T
Department of Microbiology, Kyoto Pharmaceutical University, Japan.
Antimicrob Agents Chemother. 1991 Nov;35(11):2288-93. doi: 10.1128/AAC.35.11.2288.
The activities of new quinolones against 140 strains of methicillin-resistant Staphylococcus aureus were determined. From the relationship between the MICs of sparfloxacin and ciprofloxacin, fluoroquinolone-resistant S. aureus 6171 (MIC of sparfloxacin, 200 micrograms/ml; MIC of ciprofloxacin, 100 micrograms/ml) and fluoroquinolone-susceptible S. aureus FDA 209-P were selected for purification of the subunit A and B proteins of their DNA gyrases. The supercoiling activities of reconstituted ArBr (r, resistant) (from strain 6171) and ArBs (s, susceptible) gyrases were 40-fold more resistant to new quinolones than those of AsBs from FDA 209-P and AsBr gyrases. The 50% inhibitory doses of ciprofloxacin and sparfloxacin for AmBm (from mutant 19) and AmBs (m, moderately resistant) gyrases were 15- to 27-fold higher than those for AsBs and AsBm gyrases. These findings indicate that one of the resistance mechanisms of S. aureus against fluoroquinolones is a modification of the gyrase subunit A protein.
测定了新型喹诺酮类药物对140株耐甲氧西林金黄色葡萄球菌的活性。根据司帕沙星和环丙沙星的最低抑菌浓度(MIC)之间的关系,选择耐氟喹诺酮金黄色葡萄球菌6171(司帕沙星MIC为200微克/毫升;环丙沙星MIC为100微克/毫升)和氟喹诺酮敏感金黄色葡萄球菌FDA 209 - P来纯化其DNA促旋酶的A和B亚基蛋白。重组的ArBr(r,耐药,来自菌株6171)和ArBs(s,敏感)促旋酶的超螺旋活性对新型喹诺酮类药物的耐药性比对来自FDA 209 - P的AsBs和AsBr促旋酶高40倍。环丙沙星和司帕沙星对AmBm(来自突变体19)和AmBs(m,中度耐药)促旋酶的50%抑制剂量比对AsBs和AsBm促旋酶高15至27倍。这些发现表明金黄色葡萄球菌对氟喹诺酮类药物的耐药机制之一是促旋酶亚基A蛋白的修饰。